Complex Dermal Repair for Facial Wounds and Scars

October 29, 2026 updated by: Ahmed Gamal Hemidan, Cairo University

Evaluation of Complex Dermal Layer Repair in Treatment of Facial Cut Wounds

This study evaluates a complex dermal layer repair technique for the treatment of facial wounds, with the objective of preventing scar widening and reducing scar visibility. The technique is used in patients with acute facial cut wounds and in patients undergoing facial scar revision. Scar outcomes are assessed using the Patient and Observer Scar Assessment Scale (POSAS) at six months.

Study Overview

Detailed Description

The surgical technique involves wound cleansing, local anaesthesia, de-epithelialization of one wound edge over an approximately 2 mm width, preparation of the opposing deep dermal edge, and approximation of the wound's deep layers with absorbable sutures. The de-epithelialized edge is anchored beneath the dermis of the opposing edge using 6-0 PDS sutures. The superficial skin layer is closed with 6-0 polypropylene sutures, with Steri-Strips applied as supplementary support. Skin sutures are removed within five to seven days.

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Giza, Egypt
        • Faculty of Medicine, Cairo University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 60 years (Child, Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion criteria

  • Patients aged 16-60 years.
  • Patients with acute facial cut wounds.
  • Patients who are candidates for facial scar revision.

Exclusion criteria

  • Connective tissue disease.
  • Refusal to participate.
  • Grossly contaminated wounds.
  • Wounds associated with significant skin loss.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Study group

intervention

Complex dermal layer repair

Absorbable sutures for deep-layer approximation; 6-0 PDS sutures for dermal anchoring; 6-0 polypropylene sutures for superficial skin closure; and Steri-Strips for supplementary wound support.

Other Names:
  • Skin closure

Injection of adrenaline 1:150000 solution + Lidocaine 2% by a dose suitable to the wound length (1 cc for each 1 cm)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Scar quality assessed using the Patient and Observer Scar Assessment Scale (POSAS)
Time Frame: Six months after the procedure

The Patient and Observer Scar Assessment Scale (POSAS) is a validated clinical and research tool used to evaluate scar quality from two independent perspectives: the clinician (Observer Scale) and the patient (Patient Scale).

Structure and Scoring:

  • Scoring Range: Each item is scored on a numeric scale from 1 (like normal skin) to 10 (worst scar imaginable).
  • Overall Opinion: Both the observer and the patient provide a separate overall opinion score from 1 to 10.
  • Total Score: Calculated by summing the individual item scores (ranging from 6 to 60 for each scale).
Six months after the procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2021

Primary Completion (Actual)

December 30, 2024

Study Completion (Actual)

December 30, 2024

Study Registration Dates

First Submitted

October 24, 2026

First Submitted That Met QC Criteria

October 29, 2026

First Posted (Actual)

November 3, 2026

Study Record Updates

Last Update Posted (Actual)

November 3, 2026

Last Update Submitted That Met QC Criteria

October 29, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

There is no plan to share individual participant data (IPD) collected in this study with other researchers.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe